Health

'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report

* Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy. * Details new social contribution activities that strives to support the health of its local communities. * Requires commitment to the Supplier Cod...

2022-07-11 19:00 1921

Zibo, Shandong, accelerates its transformation into the biggest pre-prepared food industrial base in northern China

ZIBO, China, July 8, 2022 /PRNewswire/ -- Themed along the lines of building a better future for the pre-prepared food industry and for enjoying the uniquely-flavored Zibo cuisine, the 2022 China (Shandong) Pre-prepared Food Industry Development Conference hosted by the Shandong Provincial Depart...

2022-07-08 17:44 2581

Industry Empowered by Science: Guangming Science City Lures Talent Globally

SHENZHEN, China, July 8, 2022 /PRNewswire/ -- The 8th Shenzhen Global Shenzhen Entrepreneurs Convention and Guangming Science City Conference kicked off on July 5, and gathered global scientists and leading entrepreneurs together to the southern Chinese city. They're invited to share their perspec...

2022-07-08 15:38 2032

Biotech Startup Noul Releases 2021 Sustainability Report

* Disclose achievement and improvement on economic, social, and environmental commitments * Contain corporate will to take sustainability as its management philosophy since its foundation * Write based on the GRI standards and self-disclose to the DART electronic disclosure system YONGIN, S...

2022-07-08 15:00 2018

NEW EARLY BREAST CANCER DRUG TO REDUCE RISK OF RECURRENCE OR DEATH NOW AVAILABLE IN THE PHILIPPINES

* NERLYNX® (neratinib) is approved by the Food and Drug Administration of the Philippines * Leading regional breast cancer oncologists say the availability of NERLYNX is a 'great step forward' for women inthe Philippines who have been diagnosed with HER2+ early-stage breast cancer * Five-y...

2022-07-08 09:28 1919

WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates

SHANGHAI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- WuXi XDC, a global leading CRDMO (Contract Research, Development and Manufacturing Organization) dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug c...

2022-07-08 09:27 4265

United Imaging To Feature Leaders of Choice Program, Innovative Purchasing Models, and World's-First Equipment at AHRA in Phoenix

Leaders of Choice is the educational program United Imaging and AHRA Announced Jointly in May. HOUSTON, July 7, 2022 /PRNewswire/ -- United Imaging confirmed that its Houston-based U.S. leadership team will be on hand in Phoenix for the AHRA (Association for Medical Imaging Management) Annual Me...

2022-07-07 20:18 1950

SunHo Announces First Patient Dosed in Phase 1/2 Clinical Trial of Two First-in-class Immunocytokines: IAP0971 and IAE0972

NANJING, China, July 7, 2022 /PRNewswire/ -- SunHo BioPharmaceutical Co., Ltd. ("SunHo"), a clinical-stage leading biopharma in immunocytokines with full-set of capabilities from discovery to commercialization, announced that IAP0971 (PD1-IL15 immunocytokine) and IAE0972 (EGFR-IL10 immunocytokine...

2022-07-07 20:00 1664

Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines

GUANGZHOU, China, July 7, 2022 /PRNewswire/ -- Recently, Zhiyi Biotech announced that it has raised$15 million in its B++ funding round. The funds will be used to boost the clinical development of the company's live biotherapeutic products (LBPs) pipelines. It's worth mentioning thatZhiyi has su...

2022-07-07 17:45 1374

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Site Enhances New Modality CRDMO Platform Capacity for Customers SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at itsChangzhou campus. The new facility underscores...

2022-07-07 08:00 3703

Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has bee...

2022-07-06 23:00 2231

I-Mab to Host 2022 R&D Day

GAITHERSBURG, MD. and SHANGHAI, July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research and Devel...

2022-07-06 20:00 1554

US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

SYDNEY, July 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib for t...

2022-07-06 19:00 2727

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene ") and HUTCHMED (China) Limited ("HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based inAustralia, was ...

2022-07-06 12:00 1677

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY ...

2022-07-06 04:16 3920

Winner Medical Acquires 100% Stake in Guilin Latex, Expanding into Medical Latex Market

SHENZHEN, China, July 5, 2022 /PRNewswire/ -- Winner Medical Co. Ltd. (300888.SZ; "Winner Medical" and "the Company"), a leading manufacturer of disposable wound care and surgical products, held an inauguration ceremony for Winner (Guilin) Latex Products Co., Ltd in Guilin,Guangxi Province on Jun...

2022-07-05 21:07 2369

EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement

FUKUOKA, Japan, July 5, 2022 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter "EditForce") has entered into a License Agreement (hereinafter "Agreement") with Mitsubishi Tanabe Pharma Corporation (Headquarters:Osaka, Representative Director: Hiro...

2022-07-05 15:00 1757

QunaSys co-hosts industry, government leaders for Pistoia Alliance Global Knowledge-Sharing virtual event

Event focuses on real-world use cases for new technologies, including quantum, poised to improve health and the life sciences TOKYO, July 4, 2022 /PRNewswire/ -- QunaSys, a global leader in the development of innovative quantum algorithms in chemistry and a Pistoia Alliance member company, will ...

2022-07-05 10:00 1762

ClinChoice Raises $150 mm Series E Round Financing, Further Strengthening its Global Services Capabilities

PHILADELPHIA, July 4, 2022 /PRNewswire/ -- Recently, ClinChoice announced the successful completion of its $150 mm Series E round financing. The investment was led by Legend Capital, and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders, including Lilly A...

2022-07-05 09:20 2083

WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products

* WuXi Biologics expands its extensive integrated CRDMO services by offering development and cGMP manufacturing for microbial-derived products. HANGZHOU, China, July 4, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing ...

2022-07-05 08:30 2345
1 ... 138139140141142143144 ... 273